

# A Cost-Effectiveness Analysis Comparing a Conventional Mechanical Needle to a Radiofrequency Device for Transseptal Punctures

## INTRODUCTION

- ▶ Previous studies have demonstrated that use of a dedicated radiofrequency (RF) transseptal puncture (TSP) device (NRG™ Transseptal Needle, Baylis Medical) is associated with reductions in transseptal complications, failures to cross the septum, and transseptal access time, as compared to use of a mechanical transseptal needle (BRK™, Abbott).
- ▶ While the upfront cost of the RF TSP device is more than the mechanical needle, the cost-effectiveness of the two options has not previously been evaluated.

## METHODS

- ▶ A decision tree was prepared to evaluate the cost-effectiveness of the RF TSP device and the mechanical needle, as used during pulmonary vein isolation (PVI) procedures, in three different clinical scenarios: single TSP with one device (base case), double TSP with one device, and double TSP with two devices.
- ▶ Probability and clinical cost inputs were located in peer-reviewed literature and healthcare databases, while costs of TSP materials were obtained from the University of California, San Francisco electrophysiology lab.
- ▶ The total cost at 30 days was the sum of PVI procedure costs and costs of TSP-related complications.
- ▶ Effectiveness was defined as probability of survival at day 30 following TSP success.
- ▶ Incremental cost-effectiveness ratios (ICER) were calculated for these four scenarios.
- ▶ One-way and Monte-Carlo probabilistic sensitivity analyses were then performed, with the latter used to prepare a cost-effectiveness acceptability curve (CEAC).

## RESULTS

- ▶ The cost-effectiveness rankings of the four scenarios are shown in Table 1.
- ▶ In all scenarios the RF TSP device was found to be dominant, as compared to the mechanical needle.
- ▶ The probabilistic sensitivity analysis and CEAC found that the RF TSP device was more cost-effective at any willingness-to-pay threshold.

## DISCUSSION AND CONCLUSIONS

- ▶ When all costs are accounted for, the RF TSP device is less costly and more effective than the mechanical needle, despite a greater upfront equipment cost.
- ▶ The modified base case analysis suggested that the shorter time-to-transseptal with the RF TSP device may further increase cost savings, which may enable faster lab turn-over and more efficient use of personnel and space.
- ▶ It is noted that variations in procedural and equipment costs between centers could influence the level of dominance or cost-effectiveness reported.

**Table 1.** Cost-Effectiveness of RF TSP device compared to mechanical needle

Scenario	Incremental Total Cost at 30 Days for RF TSP device (\$)†	Incremental Effectiveness at 30 Days for RF TSP Device (%)†	ICER‡
Single TSP with 1 device (base case)	-41	+0.9	Dominant
Double TSP with 1 device	-338	+1.1	Dominant
Double TSP with 2 devices	-158	+1.1	Dominant
Single TSP with 1 device (modified base case, with PVI costs adjusted for transseptal time savings)	-774	+0.9	Dominant

\* A wholly-owned subsidiary of Boston Scientific Corporation.

† As compared to mechanical transseptal needle

‡ The term "Dominant" indicates a device was associated with higher effectiveness and lower cost TSP denotes transseptal puncture; RF, radiofrequency; ICER, incremental cost-effectiveness ratio; PVI, pulmonary vein isolation

## Brief Summary | **NRG™** Transseptal Needle

**CAUTION:** Federal law (USA) restricts this device to sale by or on the order of a physician. Rx only. Prior to use, please see the complete "Instructions for Use" for more information on Indications, Contraindications, Warnings, Precautions, Adverse Events, and Operator's Instructions.

**INDICATIONS FOR USE:** The NRG™ Transseptal Needle is used to create an atrial septal defect in the heart. Secondary indications include monitoring intracardiac pressures, sampling blood, and infusing solutions.

**CONTRAINDICATIONS:** The NRG™ Transseptal Needle is not recommended for use with any conditions that do not require cutting or coagulation of soft tissue.

**WARNINGS:** • Laboratory staff and patients can undergo significant x-ray exposure during radiofrequency puncture procedures due to the continuous usage of fluoroscopic imaging. This exposure can result in acute radiation injury as well as increased risk for somatic and genetic effects. Therefore, adequate measures must be taken to minimize this exposure. • The NRG™ Transseptal Needle is intended for single patient use only. Do not attempt to sterilize and reuse the needle. Reuse can cause the patient injury and/or the communication of infectious disease(s) from one patient to another. Failure to do so may result in patient complications. • The NRG™ Transseptal Needle must be used with the BMC Connector Cable. Attempts to use it with other connector cables can result in electrocution of the patient and/or operator.

**PRECAUTIONS:** • Placement of the dispersive electrode on the thigh or hip could be associated with higher impedance. • In order to prevent the risk of ignition make sure that flammable material is not present in the room during RF power application. • Careful needle manipulation must be performed to avoid cardiac damage, or tamponade. Needle advancement should be done under image guidance. If resistance is encountered, DO NOT use excessive force to advance or withdraw the needle. • During power delivery, the patient should not be allowed to come in contact with ground metal surfaces. • Thoroughly flush the NRG™ Transseptal Needle with heparinized saline solution prior to use. • If using electroanatomical mapping guidance it is recommended to confirm tip placement on the fossa ovalis and septal tenting before RF puncture with graphic imaging or another imaging modality.

**ADVERSE EVENTS:** Adverse events that may occur while using the Baylis Medical Radiofrequency Puncture System include: • Tamponade • Sepsis/Infection • Thromboembolic episodes • Vessel perforation • Atrial Fibrillation • Myocardial Infarction • Vessel spasm • Sustained arrhythmias • Atrial Flutter • Hemorrhage • Vascular thrombosis • Perforation of the myocardium • Hematoma • Allergic reaction to contrast medium • Ventricular Tachycardia • Pain and Tenderness • Thermal damage to tissue • Arteriovenous fistula • Pericardial Effusion

EP-1506305-AA

All trademarks are property of their respective owners. Patents Pending and/or issued. CAUTION: The law restricts these devices to sale by or on the order of a physician. Rx only. Indications, Contraindications, Warnings, and Instructions For Use can be found in the product labelling supplied with each device or at [www.baylismedical.com](http://www.baylismedical.com).

Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries.  
This material not intended for use in France.

Boston Scientific is a Global Company. Please note that model numbers, indications, contraindications, warnings and specifications may differ depending on geographic region. Not all information displayed in this brochure may be licensed in accordance with Canadian law. Please contact your Boston Scientific representative for local labeling, product specifications and licensed model numbers.

**Boston  
Scientific**  
Advancing science for life™

© 2023 Boston Scientific Corporation  
or its affiliates. All rights reserved.

EP-1583404-AA